A Phase 3 interventional study of Granulocyte colony-stimulating factor plus plerixafor and Granulocyte colony-stimulating factor plus placebo in Lymphoma, Non-Hodgkin, sponsored by Genzyme, a Sanofi Company. Completed at 32 sites in 2 countries. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2014-03-13.
Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin — 1 open to participants now, 1 under way, none of them phase 3. Granulocyte Colony-Stimulating Factor · Lymphoma, Non-Hodgkin.
Among the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, this one has the largest enrollment, is one of 4 that started in 2005, is one of 2 in phase 3, and was the 2nd registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →1 of the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin is open now, in 1 country. Recruiting first, the newest first:
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages up to 75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 298 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 36 across the 19 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genzyme, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.
20 studies in Lymphoma, Non-Hodgkin by Sanofi: none open now, none under way, none of them phase 3. Of 19 finished, 9 (47%) have results posted.
Among the 20 studies in Lymphoma, Non-Hodgkin by Sanofi, this one has the largest enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2005, is one of 3 in phase 3, and was the 4th registered.
Sanofi’s Lymphoma, Non-Hodgkin studies by the year they started, since 2002.
1 of the studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03125642Masonic Cancer Center, University of MinnesotaAuto Stem Cell Transplant for Lymphoma Patients | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, from their registry updates:
Among Sanofi’s 20 in Lymphoma, Non-Hodgkin:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in non-Hodgkin's lymphoma patients for autologous transplantation.
A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Currently filgrastim (G-CSF), a colony stimulating factor, is used to cause the growth and mobilization of stem cells from bone marrow to peripheral blood, which can then be collected from the peripheral blood by a process called apheresis. Plerixafor aids in the release of the stem cells from the bone marrow into the peripheral blood, possibly allowing for a more rapid collection of a larger number of stem cells from the peripheral blood. Larger stem cell doses for transplantation correlate to faster recovery times after high dose chemotherapy followed with stem cell transplantation. This study is intended to determine whether the combination of plerixafor with filgrastim is better than filgrastim alone in helping non-Hodgkin's lymphoma patients collect at least 5 million stem cells in four or less apheresis sessions.
This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (Abbreviated List):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Granulocyte colony-stimulating factor plus plerixafor
Drug: Granulocyte colony-stimulating factor plus placebo
Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor
Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
Also known as: AMD3100, Mozobil
Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
Proportion of Participants Able to Achieve Target (≥ 5*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis
Proportion of participants achieving a target of ≥ 5\*10\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.
Time frame: Days 5 to 8
Number of Participants With Adverse Events
Number of participants with treatment emergent adverse events (AEs). The timeframe for treatment emergent AEs is defined as Day 1 (start of G-CSF Mobilization) to the day before starting chemotherapy (approximately 38 days later). AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale. AEs of Grade 3 were considered severe and Grade 4 were considered life-threatening.
Time frame: up to Day 38
Proportion of Participants Able to Achieve Target (>=2*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis
Proportion of participants achieving a target of \>=2\*10\^6 CD34+ Cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.
Time frame: up to Day 8
Median Number of Days of Apheresis Required to Achieve >=5*10^6 CD34+ Cells/kg
The Kaplan Meier estimate of median number of days (number of days at which 50% of participants reached the threshold, accounting for censored values) in each treatment arm to collect the target number of cells (≥5\*10\^6 CD34+ cells/kg) for transplantation. Central laboratory values were used.
Time frame: up to Day 8
Median Number of Days to Polymorphonuclear (PMN) Cell Engraftment
The Kaplan Meier estimate of median number of days to PMN engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.
Time frame: Up to Month 13
Median Number of Days to Platelet (PLT) Engraftment
The Kaplan Meier estimate of median number of days to PLT engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as ≥ 20\*10\^9/L without transfusion for the preceding 7 days. Time to engraftment corresponded to the first day that the criteria were met.
Time frame: Up to Month 13
Graft Durability at 100 Days Post Transplantation
The proportion of participants maintaining a durable graft at 100 days post transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.
Time frame: approximately Day 138
Graft Durability at 6 Months Post Transplantation
The proportion of participants maintaining a durable graft at 6 months post transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.
Time frame: approximately Month 7
Graft Durability at 12 Months Post Transplantation
The proportion of participants maintaining a durable graft 12 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.
Time frame: approximately Month 13
Participants with non-Hodgkin's lymphoma (NHL) eligible for autologous hematopoietic stem cell transplant were recruited from 31 centers in the U.S. and 1 in Canada. The first participant was randomized on 18 January 2005 and the last participant's last study visit occurred on 20 December 2007. A total of 298 participants were randomized.
| Milestone | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Started | 150 | 148 |
| Completed | 112 | 68 |
| Not completed | 38 | 80 |
| Withdrew: Entered rescue procedure | 10 | 52 |
| Withdrew: Death | 16 | 12 |
| Withdrew: Elective withdrawal | 4 | 0 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Other | 2 | 7 |
| Withdrew: Failed mobilization | 1 | 5 |
| Withdrew: Noncompliance | 0 | 1 |
Proportion of participants achieving a target of ≥ 5\*10\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.
| proportion of participants | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Proportion achieving target in ≤4 days | 0.593 | 0.196 |
| Proportion not achieving target in ≤4 days | 0.407 | 0.804 |
Number of participants with treatment emergent adverse events (AEs). The timeframe for treatment emergent AEs is defined as Day 1 (start of G-CSF Mobilization) to the day before starting chemotherapy (approximately 38 days later). AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale. AEs of Grade 3 were considered severe and Grade 4 were considered life-threatening.
| participants | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Adverse Events (AEs) | 146 | 138 |
| Related AEs | 98 | 60 |
| AEs Leading to early treatment termination | 3 | 3 |
| AEs Leading to early study termination | 2 | 4 |
| Grade 3 (severe) or 4 (life-threatening) AEs | 11 | 14 |
| SAEs | 8 | 10 |
Proportion of participants achieving a target of \>=2\*10\^6 CD34+ Cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.
| proportion of participants | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Proportion achieving target in ≤4 days | 0.867 | 0.473 |
| Proportion not achieving target in ≤4 days | 0.133 | 0.527 |
The Kaplan Meier estimate of median number of days (number of days at which 50% of participants reached the threshold, accounting for censored values) in each treatment arm to collect the target number of cells (≥5\*10\^6 CD34+ cells/kg) for transplantation. Central laboratory values were used.
| Days | G-CSF + Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Median Number of Days of Apheresis Required to Achieve >=5*10^6 CD34+ Cells/kg | 3.0 (1.0 to NA) | NA (NA to NA) |
The Kaplan Meier estimate of median number of days to PMN engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.
| Days | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Median Number of Days to Polymorphonuclear (PMN) Cell Engraftment | 10.0 (10.0 to 11.0) | 10.0 (10.0 to 11.0) |
The Kaplan Meier estimate of median number of days to PLT engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as ≥ 20\*10\^9/L without transfusion for the preceding 7 days. Time to engraftment corresponded to the first day that the criteria were met.
| Days | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Median Number of Days to Platelet (PLT) Engraftment | 20.0 (17.0 to 25.0) | 20.0 (18.0 to 25.0) |
The proportion of participants maintaining a durable graft at 100 days post transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.
| proportion of participants | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Proportion of participants with durable graft | 0.948 | 0.951 |
| Proportion of participants without durable graft | 0.052 | 0.049 |
The proportion of participants maintaining a durable graft at 6 months post transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.
| proportion of participants | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Proportion of participants with a durable graft | 0.976 | 0.987 |
| Proportion of participants without a durable graft | 0.024 | 0.013 |
The proportion of participants maintaining a durable graft 12 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.
| proportion of participants | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Proportion of participants with a durable graft | 0.982 | 1.0 |
| Proportion of participants without a durable graft | 0.018 | 0.0 |
Collected over Treatment emergent AEs covering Day 1 (start of G-CSF Mobilization to the day before starting chemotherapy (approximately Day 38).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| G-CSF Plus Plerixafor | — | 8/150 (5.3%) | 145/150 (96.7%) |
| G-CSF Plus Placebo | — | 10/145 (6.9%) | 136/145 (93.8%) |
| Event | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| Atrial fibrillationCardiac disorders | 0/150 | 2/145 |
| Abdominal pain lowerGastrointestinal disorders | 0/150 | 1/145 |
| Non-cardiac chest painGeneral disorders | 0/150 | 1/145 |
| BacteraemiaInfections and infestations | 0/150 | 1/145 |
| Bacterial sepsisInfections and infestations | 0/150 | 1/145 |
| Pseudomonal sepsisInfections and infestations | 0/150 | 1/145 |
| SinusitisInfections and infestations | 0/150 | 1/145 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/150 | 1/145 |
| Renal failure acuteRenal and urinary disorders | 0/150 | 1/145 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/150 | 0/145 |
| Event | G-CSF Plus Plerixafor | G-CSF Plus Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 65/150 | 20/145 |
| NauseaGastrointestinal disorders | 50/150 | 24/145 |
| Injection site erythemaGeneral disorders | 48/150 | 10/145 |
| Bone painMusculoskeletal and connective tissue disorders | 40/150 | 41/145 |
| FatigueGeneral disorders | 40/150 | 33/145 |
| HeadacheNervous system disorders | 37/150 | 27/145 |
| Back painMusculoskeletal and connective tissue disorders | 31/150 | 30/145 |
| ParaesthesiaNervous system disorders | 27/150 | 30/145 |
| HypokalaemiaMetabolism and nutrition disorders | 25/150 | 20/145 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 23/150 | 19/145 |
| Age, Continuous(years) | G-CSF Plus Plerixafor | G-CSF Plus Placebo | Total |
|---|---|---|---|
| Mean | 55.1 ± 10.9 | 57.5 ± 10.3 | 56.3 ± 10.7 |
| Sex: Female, Male(Participants) | G-CSF Plus Plerixafor | G-CSF Plus Placebo | Total |
|---|---|---|---|
| Female | 50 | 46 | 96 |
| Male | 100 | 102 | 202 |
| Race/Ethnicity, Customized(participants) | G-CSF Plus Plerixafor | G-CSF Plus Placebo | Total |
|---|---|---|---|
| Caucasian | 136 | 140 | 276 |
| African-American | 6 | 1 | 7 |
| Asian | 2 | 2 | 4 |
| Hispanic/Latino | 5 | 4 | 9 |
| Other | 1 | 1 | 2 |
The record gives a start of Jan 2005, a primary completion of Jul 2006 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor